The United States Patent and Trademark Office (USPTO) has granted patent US12582696B2 to Washington University. This patent covers methods for treating, selecting treatment for, and monitoring treatment of inflammatory bowel disease, specifically Crohn's disease, by utilizing the fungus Debaryomyces hansenii as a biomarker. The disclosed methods involve administering antifungal compounds and detecting biomarkers such as fungal DNA in gut microbiota or anti-fungal antibodies in blood, particularly when these biomarkers exceed a defined threshold.

While this is a patent grant and not a regulatory rule, it signifies a new intellectual property development in the therapeutic space for inflammatory bowel disease. Companies involved in developing diagnostics or treatments for Crohn's disease, particularly those focusing on antifungal therapies or microbiome analysis, should be aware of this granted patent. The patent's claims, particularly regarding the use of Debaryomyces hansenii as an indicator and the administration of antifungal compounds, may impact future research, development, and commercialization efforts in this area. No immediate compliance actions are required for regulated entities, but strategic review of patent landscapes is advised.